Statement: The most common adverse event in the primary trial was Febrile neutropenia (14.29%), whereas in the secondary trial it was a decrease in Ejection fraction (4.95%).
Primary_evidence: Adverse Events 1:   Total: 7/7 (100.00%)   Febrile neutropenia 3/7 (42.86%)   Cardiac failure 1/7 (14.29%)   Neutrophil count decreased 1/7 (14.29%)   Muscular weakness 1/7 (14.29%)   Epistaxis 1/7 (14.29%)   Interstitial lung disease 1/7 (14.29%)   Pleural effusion 2/7 (28.57%)
Secondary_evidence: Adverse Events 1:   Total: 8/101 (7.92%)   Vertigo * 1/101 (0.99%)   Infected lymphocele * 1/101 (0.99%)   Ejection fraction decreased * 5/101 (4.95%)   Lymphoedema * 1/101 (0.99%)